| Line Item | 2026-03-31 | Y/Y |
|---|---|---|
| R&D Expense | $2.4M | -74.7% |
| SG&A Expense | $8.7M | +21.0% |
| Operating Income | -$11.1M | +33.6% |
| Pre-tax Income | -$9.5M | +25.6% |
| Income Tax | -$1.7M | +46.9% |
| Net Income | -$7.8M | +18.6% |
| EPS (Basic) | -$0.47 | +40.5% |
| EPS (Diluted) | -$0.47 | +40.5% |
| Line Item | 2026-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $17.0M | -23.3% |
| Current Assets | $17.4M | -23.5% |
| Total Assets | $66.7M | -7.4% |
| Current Liabilities | $2.1M | +11.2% |
| Total Liabilities | $2.8M | -48.8% |
| Stockholders' Equity | $63.9M | -4.1% |
| Line Item | 2026-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$8.9M | +40.5% |
| Investing Cash Flow | $0 | — |
| Financing Cash Flow | $3.7M | -73.5% |
Business Overview
Grace Therapeutics is a late-stage pharmaceutical company focused on developing and commercializing products for rare and orphan diseases using novel drug delivery technologies. The company applies proprietary formulations to approved pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, and improved drug delivery. In May 2023, the company underwent strategic realignment with a new management team, streamlined R&D activities, and refocused primarily on the development of its lead candidate GTx-104, an injectable formulation of nimodipine for aneurysmal subarachnoid hemorrhage.
Forward Guidance
The company states its plan to "address the items referenced in the Complete Response Letter from the FDA related to GTx-104" and timing for "a Type A meeting scheduled with the FDA related to GTx-104" and "resubmission of a new drug application (NDA) for GTx-104 under Section 505(b)(2)." The company also indicates plans to "maximize the value of our de-prioritized drug candidates, GTx-102 and GTx-101, including through potential licensing or sale" and notes that in June 2026 it "decided to not resume internal development funding for GTx-102 or GTx-101 under our current operating plan."
Key Risk Factors
The company faces substantial risks including: (1) heavy dependence on the success of GTx-104, which received a Complete Response Letter from the FDA citing manufacturing deficiencies that may delay or prevent approval; (2) manufacturing and supply chain risks, particularly the current CMO's ability to remediate FDA-identified deficiencies in a timely manner; (3) lengthy and unpredictable regulatory approval processes with uncertain outcomes; (4) inability to establish adequate sales and marketing capabilities or enter into commercialization agreements; and (5) intellectual property challenges related to the 505(b)(2) regulatory pathway, including third-party patent infringement claims that could be costly and time-consuming to defend.